These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22159702)

  • 1. [Pharmacoeconomics in uro-oncology: the concept of QALYs].
    Poulsen Nautrup B
    Urologe A; 2011 Dec; 50(12):1573-7. PubMed ID: 22159702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of cancer therapy from the perspective of a statutory health insurance].
    Rebscher H; Schellhammer S; Kopp T; Scharnetzky E
    Urologe A; 2011 Dec; 50(12):1584-90. PubMed ID: 22159704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists.
    Camps-Herrero C; Paz-Ares L; Codes M; López-López R; Antón-Torres A; Gascón-Vilaplana P; Guillem-Porta V; Carrato A; Cruz-Hernández JJ; Caballero-Díaz C; Blasco-Cordellat A; Moreno-Nogueira JA; Díaz-Rubio E
    Clin Transl Oncol; 2014 Oct; 16(10):914-20. PubMed ID: 24924625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis.
    Robinson R
    BMJ; 1993 Oct; 307(6908):859-62. PubMed ID: 8401133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Oncology caught between economics and efficiency].
    Keil TU
    Med Klin (Munich); 2000 Jun; 95 Suppl 1():1. PubMed ID: 10941245
    [No Abstract]   [Full Text] [Related]  

  • 6. Health care economic analyses and value-based medicine.
    Brown MM; Brown GC; Sharma S; Landy J
    Surv Ophthalmol; 2003; 48(2):204-23. PubMed ID: 12686305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of obesity on cost per quality-adjusted life years gained following anterior cervical discectomy and fusion in elective degenerative pathology.
    Chotai S; Sielatycki JA; Parker SL; Sivaganesan A; Kay HL; Stonko DP; Wick JB; McGirt MJ; Devin CJ
    Spine J; 2016 Nov; 16(11):1342-1350. PubMed ID: 27394664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The QALY--a measure of social value rather than individual utility?
    Nord E
    Health Econ; 1994; 3(2):89-93. PubMed ID: 8044215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QALYs, standard gambles, and the expected budget constraint.
    Blomqvist A
    J Health Econ; 2002 Mar; 21(2):181-95. PubMed ID: 11939237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Methods of comparative economic evaluations of therapies and for rational allocation of resources across sectors of health care systems - introduction, advantages, risks].
    Wasem J; Hessel F; Kerim-Sade C
    Psychiatr Prax; 2001 Jul; 28 Suppl 1():S12-20. PubMed ID: 11533902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach.
    Safonov A; Wang S; Gross CP; Agarwal D; Bianchini G; Pusztai L; Hatzis C
    Breast Cancer Res Treat; 2016 Jan; 155(2):223-34. PubMed ID: 26749360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ethics and economics in oncology].
    Winkler E; Schildmann J
    Onkologie; 2011; 34 Suppl 1():1. PubMed ID: 21389760
    [No Abstract]   [Full Text] [Related]  

  • 15. Alternatives to the QALY measure for economic evaluations.
    Gafni A
    Support Care Cancer; 1997 Mar; 5(2):105-11. PubMed ID: 9069609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review.
    Raymakers AJN; Regier DA; Peacock SJ
    Cancer; 2020 Jan; 126(1):148-155. PubMed ID: 31544234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility analysis of cataract surgery in the second eye.
    Busbee BG; Brown MM; Brown GC; Sharma S
    Ophthalmology; 2003 Dec; 110(12):2310-7. PubMed ID: 14644712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility analysis from a societal perspective.
    Johannesson M; O'Conor RM
    Health Policy; 1997 Mar; 39(3):241-53. PubMed ID: 10165464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symposium on health economics in oncology. Freiburg, Germany, June 1995.
    Kranich AL; Gastl G; Druckrey E; Porzsolt F
    J Cancer Res Clin Oncol; 1995; 121(11):691-3. PubMed ID: 7593134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility analysis of taxane therapy.
    Yee GC
    Am J Health Syst Pharm; 1997 Dec; 54(24 Suppl 2):S11-5. PubMed ID: 9435927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.